Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

New ACAT inhibitor from Pierre Fabre

Nov. 20, 1997

Insulin therapy found useful in patients with type II diabetes

Nov. 20, 1997

Pseudopeptide derivatives of OGP and OGP(10-14) disclosed by Yissum

Nov. 20, 1997

Patent coverage obtained for SomatoKine in osteoporosis, tissue repair

Nov. 20, 1997

rhIGF-I + insulin combination tested in adolescents with IDDM

Nov. 19, 1997

Schering-Plough obtains rights to Vasomax

Nov. 18, 1997

SomatoKine shows potential for the treatment of osteoporosis

Nov. 18, 1997

Pharmacokinetic profile of Taisho's ACAT inhibitor

Nov. 18, 1997

Roche resubmits NDA for Xenical

Nov. 17, 1997

New guidelines for patients exposed to fenfluramine or dexfenfluramine

Nov. 17, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...